Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed question first answered answering member label
tabling member	label

Search

100816

	registered interest
	date	23/10/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Terminal Illnesses
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, what guidance his Department has issued to health technology appraisal committees on application of NICE's end of life criteria when appraising treatments for patients with terminal illness.
	tabling member constituency	Redcar
	tabling member printed	Ian Swales
	uin	211809
	answer	answer is ministerial correction date of answer 28/10/2014 answer text <p>The Department has not issued any such guidance. The National Institute for Health and Care Excellence is an independent body and is responsible for the development of its methods and processes.</p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 28/10/2014 14:56:20 answering member 4020 label Biography information for George Freeman
	tabling member	4045 label Biography information for Ian Swales

100817

	registered interest
	date	23/10/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Terminal Illnesses
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, what rationale lies behind NICE's advice that end-of-life criteria should only apply to medicines that extend life by at least three months.
	tabling member constituency	Redcar
	tabling member printed	Ian Swales
	uin	211807
	answer	answer is ministerial correction date of answer 28/10/2014 answer text <p>In January 2009, the National Institute for Health and Care Excellence (NICE) issued supplementary advice to its appraisal committees on appraising treatments which may be life-extending for patients, with short life expectancy, and which are licensed for indications affecting small numbers of patients with incurable illnesses.</p><p> </p><p> </p><p> </p><p>This sets out the following three criteria that must all be satisfied for this supplementary advice to be applied:</p><p> </p><p>- the treatment is indicated for patients with a short life expectancy, normally less than 24 months;</p><p> </p><p>- there is sufficient evidence to indicate that the treatment offers an extension to life, normally of at least an additional three months, compared to current NHS treatment; and</p><p> </p><p>- the treatment is licensed or otherwise indicated, for small patient populations.</p><p> </p><p> </p><p> </p><p>These criteria were developed following public consultation and set out the circumstances when NICE considers it is appropriate for its appraisal committees to apply greater flexibility in their appraisal of these treatments.</p><p> </p><p> </p><p> </p><p>The advice has now been incorporated chapter 6 of <em>Guide to the methods of technology appraisal 2013 </em>which can be found at:</p><p> </p><p> </p><p> </p><p><a href="http://www.nice.org.uk/article/pmg9/chapter/6-the-appraisal-of-the-evidence-and-structured-decision-making" target="_blank">www.nice.org.uk/article/pmg9/chapter/6-the-appraisal-of-the-evidence-and-structured-decision-making</a></p><p> </p><p> </p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 28/10/2014 14:27:08 answering member 4020 label Biography information for George Freeman
	tabling member	4045 label Biography information for Ian Swales

155929

	registered interest
	date	17/11/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Breast Cancer
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, if he will take steps to ensure that off-patent bisphosphonate drugs are made routinely available for the new indication of preventing breast cancer spreading to the bone.
	tabling member constituency	Redcar
	tabling member printed	Ian Swales
	uin	214720
	answer	answer is ministerial correction date of answer 27/11/2014 answer text <p>Research led by the University of Sheffield on the effects of bisphosphonate treatment on recurrence and cause-specific mortality in women with early breast cancer was presented in 2013. We understand that NHS England’s Breast Cancer Clinical Reference Group plans to incorporate this research into guidance it will be publishing in 2015.</p><p> </p><p> </p><p> </p><p> </p><p> </p><p> </p><p> </p><p> </p><p> </p><p> </p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 27/11/2014 16:56:11 answering member 4020 label Biography information for George Freeman
	tabling member	4045 label Biography information for Ian Swales

173200

	registered interest
	date	12/01/2015
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Pancreatic Cancer: Drugs
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, how much of the Cancer Drugs Fund was spent on pancreatic cancer drugs in each year since 2010.
	tabling member constituency	Redcar
	tabling member printed	Ian Swales
	uin	220490
	answer	answer is ministerial correction date of answer 20/01/2015 answer text <p>NHS England has advised that there is currently one anti-cancer therapy available through the Cancer Drugs Fund that is used in pancreatic cancers. This is Abraxane (albumin bound paclitaxel).</p><p> </p><p> </p><p> </p><p>NHS England has estimated that, since Abraxane was added to the national Cancer Drugs Fund list in March 2014, the estimated spend in that financial year was approximately £13,000.</p><p> </p><p> </p><p> </p><p>Based on current application rates for this drug, NHS England estimates that approximately £4.09 million will be spent on this drug in 2014-15.</p><p> </p><p> </p><p> </p><p>Prior to April 2013, information on the indication for which a cancer drug was provided through the Fund was not collected.</p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 20/01/2015 13:35:17 answering member 4020 label Biography information for George Freeman
	tabling member	4045 label Biography information for Ian Swales

513658

	registered interest
	date	18/04/2016
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Congenital Abnormalities: Databases
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, whether the postcodes for the addresses of mothers of babies born with congenital abnormalities are available on the British Isles Network of Congenital Anomaly Registers.
	tabling member constituency	Redcar
	tabling member printed	Anna Turley
	uin	34325
	answer	answer is ministerial correction date of answer 21/04/2016 answer text <p>The National Congenital Anomaly and Rare Disease Registration Service (NCARDRS) is operated by Public Health England. NCARDRS has legal permission to collect patient identifiable data without the need for individual consent. As part of this dataset, patient postcodes for individuals resident in England are recorded on the NCARDRS congenital anomaly database. Protection of individual patient data is paramount and release of this data, including postcode data, is strictly controlled.</p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 21/04/2016 07:59:54 answering member 4020 label Biography information for George Freeman
	tabling member	4449 label Biography information for Anna Turley

514064

	registered interest
	date	19/04/2016
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Congenital Abnormalities
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, by what date he expects that the population of England will be covered by the National Congenital Anomaly and Rare Disease Registration Service.
	tabling member constituency	Redcar
	tabling member printed	Anna Turley
	uin	34552
	answer	answer is ministerial correction date of answer 25/04/2016 answer text <p>Public Health England achieved complete national coverage for the National Congenital Anomalies and Rare Disease Registration Service in April 2016.</p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 25/04/2016 12:59:12 answering member 4020 label Biography information for George Freeman
	tabling member	4449 label Biography information for Anna Turley

514506

	registered interest
	date	20/04/2016
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Neural Tube Defects: Research
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, what research his Department has commissioned on the causes and consequences of neural tube defect-affected pregnancies.
	tabling member constituency	Redcar
	tabling member printed	Anna Turley
	uin	34772
	answer	answer is ministerial correction date of answer 25/04/2016 answer text <p>The Department has not recently commissioned specific research on the causes and consequences of neural tube defect-affected pregnancies.</p><p> </p><p>The Department funds the National Institute for Health Research (NIHR). A pilot randomised controlled trial led by researchers at the NIHR Biomedical Research Centre at Great Ormond Street Hospital and University College London suggests that women at risk of having children with neural tube defects may be able to reduce this risk by taking inositol (Vitamin B8) as well as folic acid during pregnancy. The findings were published in February in the British Journal of Nutrition.</p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 25/04/2016 12:55:25 answering member 4020 label Biography information for George Freeman
	tabling member	4449 label Biography information for Anna Turley